An experimental once-daily pill from Gilead Sciences helped more people with moderate to severe ulcerative colitis reach remission than a placebo in a mid-stage trial, the company reported on October 19. After 12 weeks, 31% of patients taking the highest dose were in clinical remission, compared with 8% of those on placebo, a gap of 23 percentage points.
The results come from the Phase 2 SWIFT study and were presented as a late-breaking abstract at United European Gastroenterology Week in Barcelona. The drug, called emvistegrast, is not approved anywhere, and the longer-term safety and maintenance data needed to judge it fully are still being collected.